Anakinra use in pediatric kawasaki disease: inflammation control, coronary artery outcomes, and safety
Authors' conclusion
Overall, evidence quality was judged to be low to very low according to GRADE principles due to methodological limitations and imprecision.
Study context
- Population
- Pediatric Kawasaki disease patients unresponsive to conventional therapy (IVIG-resistant)≈60 pediatric cases
- Outcome
- Efficacy and safety of anakinra in KD unresponsive to conventional therapy
Methodological detailsGRADE evidence assessment, clinical trials, observational studies and case reports, 2010–2024
- GRADE evidence assessment
- Clinical trials, observational studies and case reports, 2010–2024
Pooled result
As reported in the abstract
- Rapid fever resolution (typically within 24-48 h)
- Marked reduction in inflammatory markers, particularly CRP
- Coronary artery outcomes variable, frequently reported qualitatively; stabilization or regression of coronary dilatation in several cases (occasional regression of giant aneurysms), but progression despite therapy also observed
- No comparator groups
- Evidence quality low to very low (GRADE)
Original publication
Anakinra use in pediatric kawasaki disease: inflammation control, coronary artery outcomes, and safety. Pediatr Rheumatol Online J. Published 27 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →